Compare · NVO vs PRTA
NVO vs PRTA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 491.5x PRTA ($453.4M).
- Over the past year, NVO is down 21.8% and PRTA is up 37.8% - PRTA leads by 59.6 points.
- NVO has hit the wire 5 times in the past 4 weeks while PRTA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 22 for PRTA).
- Company
- Novo Nordisk A/S
- Prothena Corporation plc
- Price
- $50.31-2.25%
- $8.65+2.06%
- Market cap
- $222.81B
- $453.4M
- 1M return
- +15.47%
- +4.59%
- 1Y return
- -21.78%
- +37.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 22
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PRTA
- Large owner Scully William P bought $157,990 worth of Ordinary Shares (20,000 units at $7.90), increasing direct ownership by 3% to 756,000 units (SEC Form 4)
- Large owner Scully William P gifted 325,000 units of Ordinary Shares, decreasing direct ownership by 31% to 736,000 units (SEC Form 4)
- Large owner Scully William P bought $1,021,225 worth of Ordinary Shares (125,000 units at $8.17), increasing direct ownership by 13% to 1,061,000 units (SEC Form 4)
- New insider Isaacs Michael John claimed ownership of 48,825 units of Ordinary Shares (SEC Form 3)
- SEC Form 144 filed by Prothena Corporation plc
- Large owner Scully William P bought $465,295 worth of Ordinary Shares (50,000 units at $9.31), increasing direct ownership by 6% to 936,000 units (SEC Form 4)
- Large owner Scully William P bought $471,300 worth of Ordinary Shares (50,000 units at $9.43), increasing direct ownership by 6% to 886,000 units (SEC Form 4)
- Large owner Scully William P bought $981,300 worth of Ordinary Shares (100,000 units at $9.81), increasing direct ownership by 14% to 836,000 units (SEC Form 4)
- SEC Form 4 filed by Director Welch Daniel G
- SEC Form 4 filed by Director Selkoe Dennis J.